[A comparative study of survival time of surgery combined with chemotherapy and non-surgical chemotherapy in SCLC]

Zhonghua Yi Xue Za Zhi. 2010 Aug 17;90(31):2212-4.
[Article in Chinese]

Abstract

Objective: To compare the survival time of surgery combine with chemotherapy with non-surgery chemotherapy in SCLC.

Methods: 37 SCLC post operation patients were received 4-6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". 37 SCLC patients were selected be control group, whose age, stage and site of tumor were similar to surgery combine with chemotherapy group, and received 6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". Two groups were followed up 5 year and compared with the survival time.

Results: The 1, 3, 5 year survival rate of surgery combined with chemotherapy group were 72.97%, 35.13%, 21.62%. The 1, 3, 5 year survival rate of control group were 54.05%, 13.51%, 5.41%. The survival rate of stage I (P = 0.01) was significantly different, but stage II (P = 0.06) and stage III (P = 0.836) were no difference between the two group of SCLC.

Conclusion: It was found that surgery combined with chemotherapy got satisfactory effects in stage I SCLC.

Publication types

  • Comparative Study
  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Combined Modality Therapy
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Small Cell Lung Carcinoma / drug therapy*
  • Small Cell Lung Carcinoma / mortality
  • Small Cell Lung Carcinoma / surgery*
  • Survival Rate